ATE258043T1 - Langsam freisetzende zubereitung für bioaktive substanz mit einer sauren gruppe - Google Patents

Langsam freisetzende zubereitung für bioaktive substanz mit einer sauren gruppe

Info

Publication number
ATE258043T1
ATE258043T1 AT97304553T AT97304553T ATE258043T1 AT E258043 T1 ATE258043 T1 AT E258043T1 AT 97304553 T AT97304553 T AT 97304553T AT 97304553 T AT97304553 T AT 97304553T AT E258043 T1 ATE258043 T1 AT E258043T1
Authority
AT
Austria
Prior art keywords
bioactive substance
acidic group
release preparation
slow release
release
Prior art date
Application number
AT97304553T
Other languages
English (en)
Inventor
Yoshio Hata
Hikaru Taira
Jun Sato
Satoshi Iinuma
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE258043T1 publication Critical patent/ATE258043T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91Polymers modified by chemical after-treatment
    • C08G63/912Polymers modified by chemical after-treatment derived from hydroxycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97304553T 1996-06-26 1997-06-26 Langsam freisetzende zubereitung für bioaktive substanz mit einer sauren gruppe ATE258043T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16546296 1996-06-26

Publications (1)

Publication Number Publication Date
ATE258043T1 true ATE258043T1 (de) 2004-02-15

Family

ID=15812884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97304553T ATE258043T1 (de) 1996-06-26 1997-06-26 Langsam freisetzende zubereitung für bioaktive substanz mit einer sauren gruppe

Country Status (5)

Country Link
US (2) US6264970B1 (de)
EP (1) EP0815853B1 (de)
AT (1) ATE258043T1 (de)
CA (1) CA2208802A1 (de)
DE (1) DE69727262T2 (de)

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5046447B2 (ja) * 2000-08-07 2012-10-10 和光純薬工業株式会社 乳酸重合体及びその製造方法
EP1484054B1 (de) * 2002-02-22 2012-08-29 Santen Pharmaceutical Co., Ltd. Arzneimittelabgabesystem zur subkonjunktivalen verabreichung von feinen körnern
KR100709015B1 (ko) * 2002-11-13 2007-04-18 (주)아모레퍼시픽 지속적 약물방출이 가능한 고분자 미립구 및 그 제조방법
WO2005018608A1 (ja) * 2003-08-20 2005-03-03 Santen Pharmaceutical Co., Ltd. 微粒子テノン嚢下投与ドラッグデリバリーシステム
WO2005023906A1 (ja) * 2003-09-08 2005-03-17 Chugai Seiyaku Kabushiki Kaisha ヒアルロン酸修飾物、及びそれを用いた薬物担体
EP1694278A4 (de) * 2003-12-16 2009-08-12 Ipsen Pharma Glp-1 pharmazeutische zusammensetzungen
EP1699847B1 (de) * 2003-12-30 2011-04-13 3M Innovative Properties Company Herstellungsverfahren von medizinischen zusammensetzungen
EP1867334A4 (de) * 2005-02-18 2009-07-15 Santen Pharmaceutical Co Ltd Verfahren zur linderung oder vermeidung der nebenwirkung von steroid-verbindungen
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
ATE534652T1 (de) 2005-04-01 2011-12-15 Univ California Phosphono-pent-2-en-1-yl-nukleoside und analoga
EP1883406B1 (de) 2005-05-23 2016-07-06 Natural Alternatives International, Inc. Zusammensetzungen und verfahren zur anhaltenden freisetzung von beta-alanin
JP5131971B2 (ja) * 2005-12-26 2013-01-30 株式会社Lttバイオファーマ 水溶性非ペプチド性低分子薬物含有ナノ粒子
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
CN101404981A (zh) * 2006-03-13 2009-04-08 恩希赛弗制药公司 治疗舒张性心力衰竭的方法和组合物
MX2008011633A (es) 2006-03-13 2008-12-16 Activx Biosciences Inc Aminoquinolonas como inhibidores de gsk-3.
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
EP3047860A1 (de) 2006-07-20 2016-07-27 OrbusNeich Medical, Inc. Bioresorbierbare polymerzusammensetzung für eine medizinische vorrichtung
DK2066662T3 (da) 2006-09-21 2013-01-07 Kyorin Seiyaku Kk Serinhydrolaseinhibitorer
CN101687788A (zh) 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US8691321B2 (en) 2006-10-20 2014-04-08 Orbusneich Medical, Inc. Bioabsorbable polymeric composition and medical device background
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
KR20090086115A (ko) * 2006-12-22 2009-08-10 엔싸이시브 파마슈티칼즈 인코퍼레이티드 C3a 수용체의 조정제 및 이의 사용 방법
PT3202814T (pt) 2007-02-15 2019-11-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de libertação imediata reduzida e métodos de produção de polímeros
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
PT2144604E (pt) 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
AR065728A1 (es) 2007-03-15 2009-06-24 Auspex Pharmaceuticals Inc Fenetilaminas sustituidas con actividad de serotoninergico y/o norepinefrinergico
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
EP2156848A4 (de) * 2007-05-14 2012-11-28 Ltt Bio Pharma Co Ltd Niedermolekulares arzneimittelhaltiges nanoteilchen mit negativ geladener gruppe mit verzögerter freisetzung
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
KR101563018B1 (ko) * 2007-09-11 2015-10-23 교린 세이야꾸 가부시키 가이샤 Gsk-3 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론
JP5373799B2 (ja) 2007-09-12 2013-12-18 杏林製薬株式会社 Gsk−3阻害剤としてのスピロ環式アミノキノロン
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2947072T3 (en) 2008-03-17 2017-01-23 Ambit Biosciences Corp 1- (3- (6,7-DIMETHOXYQUINAZOLIN-4-YLOXY) PHENYL) -3- (5- (1,1,1-TRIFLUOR-2-METHYLPROPAN-2-YL) ISOXAZOL-3-YL) UREA AS RAF CHINESE MODULATOR IN TREATMENT OF CANCER DISEASES
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
MX2010012514A (es) * 2008-05-20 2011-05-30 Cerenis Therapeutics S A Niacina y un medicamento nsaid para tratamiento combinado.
BRPI0913677A2 (pt) 2008-07-02 2015-12-15 Idenix Pharmaceuticals Inc composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto
US8836706B2 (en) * 2008-12-18 2014-09-16 Microsoft Corporation Triggering animation actions and media object actions
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
CN105837560A (zh) 2009-02-27 2016-08-10 埃姆比特生物科学公司 调控jak激酶的喹唑啉衍生物和其使用方法
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス,インコーポレイテッド ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
AU2010221990B2 (en) * 2009-03-11 2015-06-04 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
AR075974A1 (es) 2009-03-27 2011-05-11 Pathway Therapeutics Ltd Pirimidinil y 1,3,5-triazinilbencimidazolsulfonamidas y su uso en terapia del cancer
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US20100249698A1 (en) * 2009-03-31 2010-09-30 Bordoloi Binoy K Controlled exotherm of cyanoacrylate formulations
CN102459210B (zh) 2009-04-22 2015-09-02 埃克希金医药品有限公司 芳基磺酰胺ccr3拮抗剂
HUE038507T2 (hu) 2009-04-22 2018-10-29 Sma Therapeutics Inc 2,5-diszubsztituált arilszulfonamid CCR3-antagonisták
TW201041583A (en) 2009-04-22 2010-12-01 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide CCR3 antagonists
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2451802A1 (de) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl- und 1,3,5-triazinyl-benzimidazole und ihre verwendung in der krebstherapie
US8496973B2 (en) 2009-07-08 2013-07-30 Hope Medical Enterprises, Inc. Sodium thiosulfate-containing pharmaceutical compositions
EP2467144A1 (de) 2009-07-24 2012-06-27 ViroLogik GmbH Kombination aus proteasehemmern und antihepatitismedikation zur behandlung von hepatitis
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
WO2011056566A2 (en) 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
WO2011082289A1 (en) 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
ES2632548T3 (es) 2010-02-05 2017-09-14 Tragara Pharmaceuticals, Inc. Formas de estado sólido de los inhibidores de la quinasa macrocíclica
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
AU2011223873B2 (en) 2010-03-02 2015-06-25 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
MX336559B (es) 2010-03-17 2016-01-25 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida.
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
MX2012013879A (es) 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
EP2585063A1 (de) 2010-06-01 2013-05-01 Biotheryx Inc. Verfahren zur behandlung von hämatologischen malignomen mit 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridon
JP5855095B2 (ja) 2010-06-07 2016-02-09 ノボメディックス,エルエルシーNovomedix,Llc フラニル化合物およびその使用
AU2011279808B2 (en) 2010-07-19 2015-07-02 Mayo Foundation For Medical Education And Research (Mfmer) Vitamin C and chromium-free vitamin K, and compositions thereof for treating an NFKB-mediated condition or disease
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
EP2611795B1 (de) 2010-09-01 2016-05-04 Ambit Biosciences Corporation Optisch aktives pyrazolylaminochinazolin sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US20130317045A1 (en) 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
CA2809983A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
MX2013002384A (es) 2010-09-01 2013-07-05 Ambit Biosciences Corp Compuestos quinazolina y metodos para utilizarlos.
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2627635A1 (de) 2010-10-11 2013-08-21 Axikin Pharmaceuticals, Inc. Salze aus arylsulfonamid-ccr3-antagonisten
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ,インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
EP2670396A1 (de) 2011-01-31 2013-12-11 Celgene Corporation Pharmazeutische zusammensetzungen aus cytidinanaloga und anwendungsverfahren dafür
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
AR085651A1 (es) 2011-03-11 2013-10-16 Celgene Corp Metodos para tratar cancer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
EP2691384B1 (de) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituierte aralkylamino- und heteroaralkylamino)-pyrimidinyl- und 1,3,5-triazinyl-benzimidazoles, sie enthaltende pharmazeutische zusammensetzungen und diese verbindungen zur verwendung bei der behandlung proliferativer erkrankungen
EP2691388A1 (de) 2011-03-28 2014-02-05 MEI Pharma, Inc. (kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
CA2831590A1 (en) 2011-03-28 2012-10-04 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP2768838A1 (de) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituierte 3 ', 5 '-cyclophosphate von purin-nukleotid-verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen
PT2766359T (pt) 2011-10-14 2016-07-14 Ambit Biosciences Corp Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii
EP2780467B1 (de) 2011-11-14 2018-10-17 Alfasigma S.p.A. Assays und verfahren zur auswahl eines behandlungsplans für einen patienten mit depressionen und behandlungsverfahren dafür
SG10201509139QA (en) 2011-12-19 2015-12-30 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
SG11201403433PA (en) 2011-12-21 2014-07-30 Map Pharmaceuticals Inc Novel neuromodulatory compounds
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
AU2013205306B2 (en) 2012-03-16 2015-09-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2852605B1 (de) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclische phosphat-prodrugs für hcv-infektion
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
SI2882441T1 (sl) 2012-08-09 2020-08-31 Celgene Corporation Zdravljenje bolezni v zvezi z imunskim sistemom in vnetnih bolezni
TW201408657A (zh) 2012-08-09 2014-03-01 Celgene Corp (s)-3-(4-((4-(嗎啉基甲基)苄基)氧基)-1-氧異吲哚啉-2-基)哌啶-2,6-二酮之鹽及固態形式、包含其之組合物及其使用方法
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
EP2892884A1 (de) 2012-09-07 2015-07-15 Axikin Pharmaceuticals, Inc. Isotopisch angereicherte arylsulfonamid-ccr3-antagonisten
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
PE20151318A1 (es) 2012-10-08 2015-10-03 Idenix Pharmaceuticals Inc Analogos de 2'-cloro nucleosido para infeccion por vhc
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
NZ744567A (en) 2012-11-01 2020-03-27 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
CA2890177A1 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
KR102180342B1 (ko) 2012-11-30 2020-11-18 노보메딕스 엘엘씨 치환된 바이아릴 설폰아미드 및 이의 용도
EP2935304A1 (de) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluor-nukleoside zur behandlung von hcv
BR112015014964A2 (pt) 2012-12-21 2017-07-11 Map Pharmaceuticals Inc novos derivados de metisergida
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
BR112015029969A2 (pt) 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
EP3004130B1 (de) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thionukleoside zur behandlung von hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015031613A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (de) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibitoren des hepatitis-c-virus
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環式化合物及びその使用
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (de) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanin-phosphoramidat-pronukleotide von 2'-methyl-2'-fluor-guanosin-nukleosid-verbindungen zur behandlung von hcv
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
EP3083654A1 (de) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or-nukleoside zur behandlung von hcv
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015143161A1 (en) 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
RU2741914C2 (ru) 2014-03-20 2021-01-29 Капелла Терапьютикс, Инк. Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
EP3131914B1 (de) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
RU2016148364A (ru) 2014-05-12 2018-06-13 Конатус Фармасьютикалз, Инк. Лечение осложнений хронического заболевания печени
JP2017516779A (ja) 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
PE20170268A1 (es) 2014-06-19 2017-04-21 Ariad Pharma Inc Compuestos de heteroarilo para la inhibicion de cinasa
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
MX2017003215A (es) 2014-09-12 2018-01-24 Tobira Therapeutics Inc Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN111888368B (zh) 2014-10-21 2024-02-02 武田药品工业株式会社 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
EP3209658A1 (de) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoidderivate und verfahren zur verwendung
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
AU2016209492B2 (en) 2015-01-20 2020-10-22 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
EP3303361A1 (de) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nukleotide zur behandlung von krebs
AU2016282790B9 (en) 2015-06-23 2020-01-30 Neurocrine Biosciences, Inc. VMAT2 inhibitors for treating neurological diseases or disorders
SG10202101740QA (en) 2015-08-17 2021-04-29 Kura Oncology Inc Methods of treating cancer patients with farnesyl transferase inhibitors
WO2017059385A1 (en) 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
ES2972600T3 (es) 2015-10-30 2024-06-13 Neurocrine Biosciences Inc Sales de diclorhidrato de valbenazina y polimorfos de las mismas
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP3394057B1 (de) 2015-12-23 2022-03-30 Neurocrine Biosciences, Inc. Synthetisches verfahren zur herstellung von (s)-(2r, 3r, 11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]llsochinolin-2-yl-2-amino-3-methylbutanoat-di(4-methylbenzenesulfonat)
CN108697663A (zh) 2015-12-31 2018-10-23 科内图斯医药公司 在肝病治疗中使用胱天蛋白酶抑制剂的方法
HUE051231T2 (hu) 2016-01-08 2021-03-01 Celgene Corp Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
CN108712904B (zh) 2016-01-08 2022-08-02 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
AU2017258781C1 (en) 2016-04-29 2022-03-03 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018049080A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
BR112019005337A2 (pt) 2016-09-19 2019-08-27 Mei Pharma Inc terapia combinada
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー, インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
CN110167542A (zh) 2016-11-09 2019-08-23 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
US20200078352A1 (en) 2016-12-02 2020-03-12 Neurocrine Biosciences, Inc. Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
CN110769826A (zh) 2017-01-27 2020-02-07 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
EP3432883B1 (de) 2017-02-21 2021-07-28 Kura Oncology, Inc. Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018175324A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
AU2018246138A1 (en) 2017-03-27 2019-08-29 The Regents Of The University Of California Compositions and method of treating cancer
CN110914276A (zh) 2017-03-29 2020-03-24 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
CA3058214A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MA49140A (fr) 2017-05-19 2020-03-25 Nflection Therapeutics Inc Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
US11161845B2 (en) 2017-05-19 2021-11-02 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
AU2018275873A1 (en) 2017-06-01 2019-12-19 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
MY200746A (en) 2017-08-07 2024-01-13 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MA50175A (fr) 2017-09-21 2021-04-21 Neurocrine Biosciences Inc Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
CN111836543A (zh) 2017-10-10 2020-10-27 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
EP3814327A1 (de) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorphenoxy)pentansäure-derivate und verwandte verbindungen als caspase-inhibitoren zur behandlung kardiovaskulärer erkrankungen
AU2019322863A1 (en) 2018-08-15 2021-03-11 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CA3117968A1 (en) 2018-11-01 2020-05-07 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020106303A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
EP3883554A4 (de) 2018-11-20 2022-11-23 NFlection Therapeutics, Inc. Aryl-anilin- und heteroaryl-anilinverbindungen zur behandlung von muttermalen
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン-アニリン化合物
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
SG11202106599WA (en) 2018-12-21 2021-07-29 Kura Oncology Inc Therapies for squamous cell carcinomas
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW202100506A (zh) 2019-03-07 2021-01-01 美商柯納特斯製藥公司 半胱天冬酶(caspase)抑制劑及其使用方法
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2021007474A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP3997068A1 (de) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfonverbindungen und pharmazeutische zusammensetzungen daraus sowie ihre therapeutischen anwendungen zur behandlung von neurodegenerativen erkrankungen
WO2021021563A1 (en) 2019-07-26 2021-02-04 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
MX2022003166A (es) 2019-09-16 2022-06-29 Dice Alpha Inc Moduladores de il-17a y usos de los mismos.
WO2021059023A1 (en) 2019-09-26 2021-04-01 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20220091488A (ko) 2019-10-01 2022-06-30 몰레큘러 스킨 테라퓨틱스, 인코포레이티드 Klk5/7 이중 억제제로서의 벤족사지논 화합물
CN111423568B (zh) * 2020-03-06 2022-09-27 天津大学 聚乙二醇与氨基修饰的聚己内酯三嵌段共聚物及其纳米粒、温敏凝胶和应用
EP4157271A1 (de) 2020-05-29 2023-04-05 Boulder Bioscience LLC Verfahren zur verbesserten endovaskulären thrombektomie mit 3,3'-diindolylmethan
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
BR112023002659A2 (pt) 2020-08-14 2023-05-02 Siteone Therapeutics Inc Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor
WO2022164997A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
US20240208968A1 (en) 2021-03-10 2024-06-27 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (de) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryldiamid-ire1/xbp1s-aktivatoren
CA3236150A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
CN114010795B (zh) * 2021-11-25 2024-01-02 华中药业股份有限公司 一种改性土茯苓缓释材料的制备方法及其应用
AU2022399572A1 (en) 2021-11-30 2024-05-02 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023192817A1 (en) 2022-03-28 2023-10-05 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2023201282A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2023215781A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
WO2024086246A2 (en) 2022-10-18 2024-04-25 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
WO2024092037A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
US20240174695A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds
WO2024092043A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793279A (fr) 1971-12-30 1973-06-22 Ici Ltd Agents dispersants
US4182654A (en) * 1974-09-18 1980-01-08 Pierce Chemical Company Production of polypeptides using polynucleotides
DE3937283A1 (de) 1989-11-09 1991-05-16 Hoechst Ag Polyelektrolytkomplexe zur behandlung und prophylaxe von viruserkrankungen, neue polyelektrolytkomplexe sowie verfahren zu deren herstellung
DE4224401A1 (de) 1992-07-21 1994-01-27 Pharmatech Gmbh Neue biologisch abbaubare Polymere für die Arzneistoffgalenik
SG47043A1 (en) 1993-01-06 1998-03-20 Kinerton Ltd Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides
WO1994021229A1 (en) 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US5733762A (en) * 1994-04-28 1998-03-31 I.D.M. Immuno-Designed Molecules Complexes of nucleic acid and polymer, their process of preparation and their use for the transfection of cells
US5840338A (en) * 1994-07-18 1998-11-24 Roos; Eric J. Loading of biologically active solutes into polymer gels
US5654381A (en) 1995-06-16 1997-08-05 Massachusetts Institute Of Technology Functionalized polyester graft copolymers

Also Published As

Publication number Publication date
DE69727262D1 (de) 2004-02-26
EP0815853A3 (de) 1998-12-02
DE69727262T2 (de) 2004-07-01
US20010038854A1 (en) 2001-11-08
US6264970B1 (en) 2001-07-24
US6696500B2 (en) 2004-02-24
EP0815853A2 (de) 1998-01-07
EP0815853B1 (de) 2004-01-21
CA2208802A1 (en) 1997-12-26

Similar Documents

Publication Publication Date Title
ATE258043T1 (de) Langsam freisetzende zubereitung für bioaktive substanz mit einer sauren gruppe
DE69332210D1 (de) Biologisch abbaubares, schmelzgesponnenes abgabesystem zur kontrollierten freisetzung
MX9205998A (es) Sistema automatico para la distribucion de llamadas telefonicas.
BR0010659B1 (pt) mÉtodo para a fabricaÇço de artigo absorvente tendo recurso de fixaÇço com pequena auto-adesço.
DK0904480T3 (da) Automatisk selvaktiverende stopkrave
DE69023444D1 (de) Absorbierbare chirurgische Klammer.
NO942477D0 (no) Opioide formuleringer med forlenget, regulert frigivelse
IT1303444B1 (it) Dispositivo di rilascio di farmaci.
ATE243488T1 (de) Absorbierende artikel mit trennmittel
ES1033552Y (es) Jeringa automatica, presurizada y precargada.
ES2185911T3 (es) Composiciones farmaceuticas que contienen polimeros de ortoester tamponados.
MX9203070A (es) Compuestos con propiedades inhibidoras de la renina, procedimiento para su preparacion y su empleo.
ES1035958Y (es) Dispositivo para el control de la incontinencia masculina.
MX9205982A (es) Agente para la preparacion de fibras, degradable biologicamente.
BR9510333A (pt) Sistema catalisador para a preparação de um copolímero semelhante a borracha
DE59509969D1 (de) Wegfahrsperre mit kurzer entriegelungszeit
FI915861A0 (fi) En komposition speciellt foer underlagsbelaeggning som baserar sig pao polyfosfazen.
NO932070L (no) Vandig, polymert viskositeitsoekende preparat
ES1023583Y (es) Ancla perfeccionada.
ES1014887Y (es) Dispositivo para el control de la incontinencia masculina.
ES1030652Y (es) Ancla perfeccionada.
ES1026166Y (es) Baliza de señalizacion perfeccionada.
ES1033845Y (es) Cateter para inseminacion artificial mejorado.
ES1026931Y (es) Protector plastico para farolas.
ES1014776Y (es) Clip para sutura mecanica dermica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties